First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

The Lancet Oncology

Topics

Medicine

Cancer Oncology

Immunology

Internal Medicine

Genetics

Show all topics

DOI

10.1016/s1470-2045(24)00196-7

License

CC-BY

Other Formats

PDF